Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886014 | PMC |
| http://dx.doi.org/10.1016/j.eclinm.2022.101311 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study.
J Neurol
January 2025
Clinical and Molecular Epidemiology, IRCCS San Raffaele Roma, Rome, Italy.
Objectives: To determine whether extending anti-CGRP mAb treatment beyond 3 years influences migraine course, we analyzed migraine frequency during the first month of treatment discontinuation following three 12-month treatment cycles (Ts).
Methods: This multicenter, prospective, real-world study enrolled 212 patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM) who completed three consecutive Ts of subcutaneous anti-CGRP mAbs. Discontinuation periods (D1, D2, D3) were defined as the first month after T1, T2, and T3, respectively.
Yield and Sensorial and Nutritional Quality of Strawberry ( × Duch.) Fruits from Plants Grown Under Different Amounts of Irrigation in Soilless Cultivation.
Plants (Basel)
January 2025
Department of Agricultural, Food and Environmental Sciences, Università Politecnica delle Marche (UNIVPM), Via Brecce Bianche 10, 60131 Ancona, Italy.
Water scarcity is an ecological issue affecting over 10% of Europe. It is intensified by rising temperatures, leading to greater evaporation and reduced precipitation. Agriculture has been confirmed as the sector accounting for the highest water consumption globally, and it faces significant challenges relating to drought, impacting crop yields and food security.
View Article and Find Full Text PDFInnate and SARS-CoV-2 specific adaptive immune response kinetic in neutralizing monoclonal antibody successfully treated COVID-19 patients.
Int Immunopharmacol
January 2025
Unit of Pathogen Specific Immunity, Bambino Gesù Children's Hospital, IRCCS, Rome 00146 Italy. Electronic address:
The impact of anti-Spike monoclonal antibody (mAbs) treatment on the immune response of COVID19-patients is poorly explored. In particular, a comparison of the immunological influence of different therapeutic regimens has not yet been performed. Aim of the study was to compare the kinetic of innate and adaptive immune response as well as the SARS-CoV-2 specific humoral and T cell response in two groups of SARS-CoV-2-infected patients treated with two different mAbs regimens: Bamlanivimab/Etesevimab (BAM/ETE) or Casirivimab/Imdevimab (CAS/IMD).
View Article and Find Full Text PDFImpact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
Ann Hematol
January 2025
Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.
Calreticulin (CALR) mutations are detected in around 20% of patients with primary and post-essential thrombocythemia myelofibrosis (MF). Regardless of driver mutations, patients with splenomegaly and symptoms are generally treated with JAK2-inhibitors, most commonly ruxolitinib. Recently, new therapies specifically targeting the CALR mutant clone have entered clinical investigation.
View Article and Find Full Text PDFA combined experimental-computational approach for retinal characterization.
Exp Eye Res
January 2025
Department of Chemistry, Materials and Chemical Engineering "Giulio Natta" (LaBS), Politecnico di Milano, Milano, Italy. Electronic address:
Subretinal injection of gene products is the only treatment option for inherited retinal diseases. However, this procedure induces localized high multiaxial deformations, potentially causing irreversible tissue damage due to retinal overstretching and tearing. Comprehensive characterization of retinal mechanical behavior is essential for performing safe injections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!